MediWound announced its successful participation at the recently concluded 20th European Burns Association, EBA, Congress held in Nantes, France on September 6-9, 2023. NexoBrid was featured in 20 scientific oral and poster presentations over the Congress’ four days. Leaders in the field of burn care presented and demonstrated their experience and observations of patient outcomes with NexoBrid in a wide range of settings. “We are delighted that NexoBrid was featured so extensively at this year’s European Burn Association Congress, one of the top platforms to exchange knowledge and experiences in burn care.” stated Ofer Gonen, Chief Executive Officer of MediWound. “As we continue our mission of advancing global burn care, we are honored that the event allowed us to share the latest research findings from the collaborative work of our scientists and prominent burn specialists, showcasing NexoBrid’s application in various scenarios, including routine and mass casualties for both adults and pediatric patients.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDWD:
- MediWound price target lowered to $36 from $63 at Oppenheimer
- MediWound enters research collaboration agreement with MiMedx
- MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study
- MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study
- MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update
